A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引：45
|
作者：
Wu, Xiujuan [1 ]
Tang, Peng [1 ]
Li, Shifei [1 ]
Wang, Shushu [1 ]
Liang, Yueyang [1 ]
Zhong, Ling [1 ]
Ren, Lin [1 ]
Zhang, Ting [1 ]
Zhang, Yi [1 ]
机构：
[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China
来源：
NATURE COMMUNICATIONS | 2018年 / 9卷
关键词：
PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;
D O I：
10.1038/s41467-018-03210-2
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial
    Yan, Wenting
    Wu, Xiujuan
    Wang, Shushu
    He, Cheng
    Zhong, Ling
    Tang, Peng
    Ren, Lin
    Zhang, Ting
    Qi, Xiaowei
    Zhang, Yi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [2] A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
    Yan, Min
    Yuan, Peng
    Ouyang, Quchang
    Cheng, Ying
    Han, Guohui
    Wang, Dewei
    Ran, Li
    Sun, Tao
    Zhao, Da
    Bai, Yuju
    Yang, Shun'e
    Wang, Xiaojia
    Wu, Rong
    Zeng, Xiaohua
    Yao, Herui
    Ji, Xuening
    Jiang, Jun
    Hu, Xiaohua
    Lin, Haifeng
    Zheng, Liping
    Zhu, Zhitu
    Ge, Wei
    Yang, Junlan
    Cui, Tongjian
    Zhang, Xiaozhi
    Lu, Fangyang
    Li, Wenhui
    Xu, Hongyan
    Kang, Mafei
    Gong, Ping
    Zou, Liqun
    Liu, Jiang
    Zhang, Hongliang
    Yu, Hao
    Xu, Binghe
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [3] Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
    Smith, John W., II
    McIntyre, Kristi J.
    Acevedo, Patrick V.
    Encarnacion, Carlos A.
    Tedesco, Karen L.
    Wang, Yunfei
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (02) : 361 - 367
  • [4] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [5] Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer
    Clavarezza, Matteo
    Turazza, Monica
    Aitini, Enrico
    Saracchini, Silvana
    Garrone, Ornella
    Durando, Antonio
    De Placido, Sabino
    Bisagni, Giancarlo
    Levaggi, Alessia
    Bighin, Claudia
    Restuccia, Eleonora
    Scalamogna, Roberto
    Galli, Anna
    Del Mastro, Lucia
    BREAST, 2013, 22 (04) : 470 - 475
  • [6] Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial
    Zhang, Liulu
    Wu, Zhi-Yong
    Li, Jie
    Lin, Ying
    Liu, Zhenzhen
    Cao, Yin
    Zhang, Gangling
    Gao, Hong-Fei
    Yang, Mei
    Yang, Ci-Qiu
    Zhu, Teng
    Cheng, Min-Yi
    Ji, Fei
    Li, Jieqing
    Wang, Kun
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 654 - 662
  • [7] Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
    Liu, Jieqiong
    Liu, Qiang
    Li, Ying
    Li, Qian
    Su, Fengxi
    Yao, Herui
    Su, Shicheng
    Wang, Quanren
    Jin, Liang
    Wang, Ying
    Lau, Wan Yee
    Jiang, Zefei
    Song, Erwei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [8] Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
    Huang, Liang
    Chen, Sheng
    Yang, Wentao
    Xu, Binghe
    Huang, Tao
    Yang, Hongjian
    Zheng, Hong
    Wang, Yongsheng
    Song, Erwei
    Zhang, Jin
    Cui, Shude
    Pang, Da
    Tang, Lili
    Lei, Yutao
    Geng, Cuizhi
    Shao, Zhiming
    ONCOTARGET, 2015, 6 (21) : 18683 - 18692
  • [9] Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
    Wang, Cheng
    Yuan, Long
    Wu, Xiujuan
    Wang, Yan
    Tian, Hao
    Zhang, Guozhi
    Wan, Andi
    Xiong, Siyi
    Wang, Chengfang
    Zhou, Yuqin
    Ma, Dandan
    Bao, Yangqiu
    Qu, Man
    Jiang, Jun
    Zhang, Yi
    Qi, Xiaowei
    BMC MEDICINE, 2024, 22 (01):
  • [10] Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
    Guo, Honghai
    Ding, Ping'an
    Sun, Chenyu
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Lowe, Scott
    Bentley, Rachel
    Li, Yaru
    Zhang, Zhidong
    Wang, Dong
    Li, Yong
    Zhao, Qun
    FRONTIERS IN ONCOLOGY, 2022, 12
12345